Enveric Biosciences (ENVB) EBIT Margin (2014 - 2020)
Enveric Biosciences (ENVB) posted EBIT Margin of 5.77% for Q3 2020, up 37.89% sequentially from 9.3% in Q2 2020, and up 1133.0% YoY from 0.47% in Q4 2019.
Enveric Biosciences (ENVB) EBIT Margin (2014 - 2020) Analysis & Trends
Enveric Biosciences has reported EBIT Margin for 7 years, with the latest figure at 5.77% in Q3 2020.
- Quarterly EBIT Margin rose 1133.0% year-over-year to 5.77% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 0.14% (up 3666.0% YoY) and the FY2019 annual result came in at 5.75%, up 1087.0% from the prior year.
- EBIT Margin climbed to 5.77% in Q3 2020 per ENVB's latest filing, from 9.3% in the prior quarter.
- Over five years, EBIT Margin peaked at 57.68% in Q3 2018 and troughed at 105.03% in Q4 2018.
- A 5-year average of 13.94% and a median of 12.84% in 2016 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2018 and 2019: EBIT Margin plunged 7699 bps in 2018, then soared 12757 bps in 2019.
- Over 5 years, EBIT Margin stood at 17.52% in 2016, then sank by 60 bps to 28.04% in 2017, then sank by 275 bps to 105.03% in 2018, then jumped by 121 bps to 22.54% in 2019, then plunged by 126 bps to 5.77% in 2020.
- According to Business Quant data, EBIT Margin over the past three periods registered 5.77%, 9.3%, and 8.71% for Q3 2020, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -5.77% |
| Jun 30, 2020 | -9.30% |
| Mar 31, 2020 | -8.71% |
| Dec 31, 2019 | 22.54% |
| Sep 30, 2019 | -17.11% |
| Jun 30, 2019 | -13.40% |
| Mar 31, 2019 | -12.15% |
| Dec 31, 2018 | -105.03% |
| Sep 30, 2018 | 57.68% |
| Jun 30, 2018 | -9.75% |
| Mar 31, 2018 | -12.35% |
| Dec 31, 2017 | -28.04% |
| Sep 30, 2017 | -31.49% |
| Jun 30, 2017 | -28.60% |
| Mar 31, 2017 | -5.11% |
| Dec 31, 2016 | -17.52% |
| Sep 30, 2016 | -12.84% |
| Jun 30, 2016 | -14.01% |
| Mar 31, 2016 | -13.99% |
| Dec 31, 2015 | -22.88% |